基于AHP-FCE模型的制药废水处理技术综合评价

制药废水由于具有水质复杂、COD高、有毒有害物浓度高、可生化性差、色度高等特点,处理十分困难。目前制药废水处理技术种类较多,且各项技术均具有各自的特点。为选择合适的制药废水处理技术,构建了制药废水处理技术评价指标体系,确定了评价标准,并采用层次分析法与模糊综合评价法相结合的评价方法(AHP-FCE)对国家水体污染控制与治理科技重大专项(简称“水专项”)研发的13项制药废水处理技术进行了综合评价。结果表明:升流式厌氧污泥床-膜生物反应器(UASB-MBR)组合技术是制药废水处理较优的可行技术,其次为两级分离内循环厌氧反应器和复合氧反应器-好氧反应器(ABR-CASS)生物强化处理技术。研究结果可以为制药企业选择合适的废水处理技术提供支持。

Comprehensive evaluation of wastewater treatment technology in pharmaceutical industry based on AHP-FCE model

Pharmaceutical wastewater is difficult to be treated because of its complex water quality, high COD, high content of toxic and harmful substances, poor biodegradability and high chrominance. There are many kinds of pharmaceutical wastewater treatment technologies, and each technology has its own characteristics. In order to correctly select the appropriate pharmaceutical wastewater treatment technologies, the evaluation index system and the evaluation standard of the wastewater treatment technologies in pharmaceutical industry were established. The analytic hierarchy process and fuzzy comprehensive evaluation (AHP-FCE) method was used to comprehensively evaluate 13 pharmaceutical wastewater treatment technologies supported by National Major Scientific and Technological Special Projects for Water Pollution Control and Management (Major Water Project). The results showed that UASB-MBR was a more feasible pharmaceutical wastewater treatment technology among the 13 technologies, followed by two-stage separation internal circulation anaerobic reactor and ABR-CASS biological enhancement technology. The results could provide strong support for pharmaceutical enterprises to choose appropriate wastewater treatment technologies.